These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 38600391)

  • 1. FOXO1 is a master regulator of memory programming in CAR T cells.
    Doan AE; Mueller KP; Chen AY; Rouin GT; Chen Y; Daniel B; Lattin J; Markovska M; Mozarsky B; Arias-Umana J; Hapke R; Jung IY; Wang A; Xu P; Klysz D; Zuern G; Bashti M; Quinn PJ; Miao Z; Sandor K; Zhang W; Chen GM; Ryu F; Logun M; Hall J; Tan K; Grupp SA; McClory SE; Lareau CA; Fraietta JA; Sotillo E; Satpathy AT; Mackall CL; Weber EW
    Nature; 2024 May; 629(8010):211-218. PubMed ID: 38600391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOXO1 is a master regulator of CAR T memory programming.
    Doan A; Mueller KP; Chen A; Rouin GT; Daniel B; Lattin J; Chen Y; Mozarsky B; Markovska M; Arias-Umana J; Hapke R; Jung I; Xu P; Klysz D; Bashti M; Quinn PJ; Sandor K; Zhang W; Hall J; Lareau C; Grupp SA; Fraietta JA; Sotillo E; Satpathy AT; Mackall CL; Weber EW
    Res Sq; 2023 Nov; ():. PubMed ID: 37986944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy.
    Chan JD; Scheffler CM; Munoz I; Sek K; Lee JN; Huang YK; Yap KM; Saw NYL; Li J; Chen AXY; Chan CW; Derrick EB; Todd KL; Tong J; Dunbar PA; Li J; Hoang TX; de Menezes MN; Petley EV; Kim JS; Nguyen D; Leung PSK; So J; Deguit C; Zhu J; House IG; Kats LM; Scott AM; Solomon BJ; Harrison SJ; Oliaro J; Parish IA; Quinn KM; Neeson PJ; Slaney CY; Lai J; Beavis PA; Darcy PK
    Nature; 2024 May; 629(8010):201-210. PubMed ID: 38600376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NR4A transcription factors limit CAR T cell function in solid tumours.
    Chen J; López-Moyado IF; Seo H; Lio CJ; Hempleman LJ; Sekiya T; Yoshimura A; Scott-Browne JP; Rao A
    Nature; 2019 Mar; 567(7749):530-534. PubMed ID: 30814732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy.
    Klebanoff CA; Crompton JG; Leonardi AJ; Yamamoto TN; Chandran SS; Eil RL; Sukumar M; Vodnala SK; Hu J; Ji Y; Clever D; Black MA; Gurusamy D; Kruhlak MJ; Jin P; Stroncek DF; Gattinoni L; Feldman SA; Restifo NP
    JCI Insight; 2017 Dec; 2(23):. PubMed ID: 29212954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOXO1 enhances CAR T cell fitness and function.
    Marchal I
    Nat Biotechnol; 2024 May; 42(5):699. PubMed ID: 38760553
    [No Abstract]   [Full Text] [Related]  

  • 7. Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity.
    Torres Chavez A; McKenna MK; Canestrari E; Dann CT; Ramos CA; Lulla P; Leen AM; Vera JF; Watanabe N
    J Immunother Cancer; 2019 Nov; 7(1):330. PubMed ID: 31779709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR T Cells Generated Using Sleeping Beauty Transposon Vectors and Expanded with an EBV-Transformed Lymphoblastoid Cell Line Display Antitumor Activity In Vitro and In Vivo.
    Chicaybam L; Abdo L; Carneiro M; Peixoto B; Viegas M; de Sousa P; Fornazin MC; Spago MC; Albertoni Laranjeira AB; de Campos-Lima PO; Nowill A; Barros LRC; Bonamino MH
    Hum Gene Ther; 2019 Apr; 30(4):511-522. PubMed ID: 30793967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regnase-1 suppresses TCF-1+ precursor exhausted T-cell formation to limit CAR-T-cell responses against ALL.
    Zheng W; Wei J; Zebley CC; Jones LL; Dhungana Y; Wang YD; Mavuluri J; Long L; Fan Y; Youngblood B; Chi H; Geiger TL
    Blood; 2021 Jul; 138(2):122-135. PubMed ID: 33690816
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
    Front Immunol; 2022; 13():770132. PubMed ID: 35154098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype.
    Gargett T; Truong N; Ebert LM; Yu W; Brown MP
    Cytotherapy; 2019 Jun; 21(6):593-602. PubMed ID: 30975603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells.
    Bai Z; Lundh S; Kim D; Woodhouse S; Barrett DM; Myers RM; Grupp SA; Maus MV; June CH; Camara PG; Melenhorst JJ; Fan R
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors.
    Marchais M; Simula L; Phayanouvong M; Mami-Chouaib F; Bismuth G; Decroocq J; Bouscary D; Dutrieux J; Mangeney M
    Cancer Immunol Res; 2023 Nov; 11(11):1508-1523. PubMed ID: 37649096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
    Lee MY; Robbins Y; Sievers C; Friedman J; Abdul Sater H; Clavijo PE; Judd N; Tsong E; Silvin C; Soon-Shiong P; Padget MR; Schlom J; Hodge J; Hinrichs C; Allen C
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of Antitumor Effects of CAR-T Cells in Mice with Solid Tumors.
    Rodriguez-Garcia A; Watanabe K; Guedan S
    Methods Mol Biol; 2020; 2086():251-271. PubMed ID: 31707682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia.
    Kong W; Dimitri A; Wang W; Jung IY; Ott CJ; Fasolino M; Wang Y; Kulikovskaya I; Gupta M; Yoder T; DeNizio JE; Everett JK; Williams EF; Xu J; Scholler J; Reich TJ; Bhoj VG; Haines KM; Maus MV; Melenhorst JJ; Young RM; Jadlowsky JK; Marcucci KT; Bradner JE; Levine BL; Porter DL; Bushman FD; Kohli RM; June CH; Davis MM; Lacey SF; Vahedi G; Fraietta JA
    J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34396987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic reprogramming of CAR T cells for in vivo functional persistence against solid tumors.
    Saitakis M
    Genes Immun; 2024 Oct; 25(5):434-436. PubMed ID: 38388813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric Antigen Receptor Designed to Prevent Ubiquitination and Downregulation Showed Durable Antitumor Efficacy.
    Li W; Qiu S; Chen J; Jiang S; Chen W; Jiang J; Wang F; Si W; Shu Y; Wei P; Fan G; Tian R; Wu H; Xu C; Wang H
    Immunity; 2020 Aug; 53(2):456-470.e6. PubMed ID: 32758419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A metabolic switch to memory CAR T cells: Implications for cancer treatment.
    Rostamian H; Fallah-Mehrjardi K; Khakpoor-Koosheh M; Pawelek JM; Hadjati J; Brown CE; Mirzaei HR
    Cancer Lett; 2021 Mar; 500():107-118. PubMed ID: 33290868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.